Roivant (ROIV) and Priovant announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 at Week 52.

Related Keywords

Matt Gline , More Such Health News , Systemic Lupus Erythematosus Responder Index , Systemic Lupus Erythematosus , Roivant , Riovant ,